Dynamics of KRAS G12/13 allele burden in circulating tumor DNA predicts survival in patients with unresectable pancreatic cancer undergoing palliative chemotherapy

被引：0
|
作者：
Johansen, J. S. [1 ]
Vibat, C. R. T. [2 ]
Hancock, S. [2 ]
Chen, I. [1 ]
Samuelsz, E. [2 ]
Collisson, E. A. [3 ]
Jensen, B. V. [1 ]
Melnikova, V. [2 ]
Erlander, M. G. [2 ]
机构：
[1] Herlev Hosp, Onkol Afd R, DK-2730 Herlev, Denmark
[2] Trovagene, Res & Dev, San Diego, CA USA
[3] Univ Calif San Francisco, Dept Oncol, San Francisco, CA 94143 USA
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)31317-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2401
引用
收藏
页码：S470 / S471
页数：2
相关论文
共 22 条
  • [21] Preliminary safety, antitumor activity, and circulating tumor DNA (ctDNA) changes with RMC-9805, an oral, RAS(ON) G12D-selective tri-complex inhibitor in patients with KRAS G12D pancreatic ductal adenocarcinoma (PDAC) from a phase 1 study in advanced solid tumors.
    Spira, Alexander I.
    Papadopoulos, Kyriakos P.
    Kim, Dae Won
    Parikh, Aparna Raj
    Barve, Minal A.
    Powderly, John D.
    Starodub, Alexander
    Strickler, John H.
    Li, Bob T.
    Oberstein, Paul Eliezer
    Hassan, Faisal
    Yang, Michelle
    Mccleland, Mark
    Lally, Satwant
    Lin, Wei
    Sohoni, Sophia
    Hong, David S.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 724 - 724
  • [22] Circulating tumor DNA (ctDNA) dynamics and survival outcomes in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and high (>50%) programmed cell death-ligand 1 (PD-L1) expression, randomized to cemiplimab (cemi) vs chemotherapy (chemo)
    Vokes, Natalie I.
    Gandara, David R.
    Sezer, Ahmet
    Kilickap, Saadettin
    Gumus, Mahmut
    Bondarenko, Igor
    Ozguroglu, Mustafa
    Gogishvili, Miranda
    Turk, Haci M.
    Cicin, Irfan
    Bentsion, Dmitry
    Liu, Jinrui
    Giangreco, Nicholas
    Wang, Fang
    Li, Siyu
    Lowy, Israel
    Pouliot, Jean-Francois
    Gullo, Giuseppe
    Rietschel, Petra
    Jankovic, Vladimir
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
123